{"id":"NCT02781727","sponsor":"Ascendis Pharma Endocrinology Division A/S","briefTitle":"A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)","officialTitle":"A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-13","primaryCompletion":"2019-01-17","completion":"2019-01-17","firstPosted":"2016-05-24","resultsPosted":"2022-01-04","lastUpdate":"2022-01-04"},"enrollment":162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Hormone Deficiency, Pediatric","hGH (Human Growth Hormone)","Endocrine System Diseases","Hormones","Pituitary Diseases"],"interventions":[{"type":"DRUG","name":"Once weekly subcutaneous injection of TransCon hGH","otherNames":[]},{"type":"DRUG","name":"Once daily subcutaneous injection of Genotropin","otherNames":[]}],"arms":[{"label":"TransCon hGH","type":"EXPERIMENTAL"},{"label":"human growth hormone (Genotropin)","type":"ACTIVE_COMPARATOR"}],"summary":"A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russia, Turkey, Ukraine, and the United States.","primaryOutcome":{"measure":"Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment Groups","timeFrame":"52 weeks","effectByArm":[{"arm":"Lonapegsomatropin","deltaMin":11.17,"sd":0.23},{"arm":"Daily hGH","deltaMin":10.31,"sd":0.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0088"}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":53,"countries":["United States","Armenia","Australia","Belarus","Bulgaria","Georgia","Greece","Italy","New Zealand","Poland","Romania","Russia","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["34272849"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":105},"commonTop":["Pyrexia","Nasopharyngitis","Pharyngitis","Headache","Cough"]}}